SLC5A2 and pancreatitis: Notably, it remains to be determined whether the observed pancreatitis is solely attributable to SGLT2 inhibitors or from the combined therapy regimen in this case and whether a genetic predisposition may contribute to the development of adverse drug reactions in certain individuals more than others.